Obesity candidate dropped but other progress for Shionogi pipeline
This article was originally published in Scrip
Shionogi has finally decided to call time on its once big hope for obesity velneperit (S-2367), dropping the remaining Japanese development program for the first-in-class oral neuropeptide Y Y5 receptor antagonist at the Phase IIb stage.
You may also be interested in...
The alliance between China’s largest insurance group and Shionogi takes concrete shape as investment plans and new Asia companies move ahead, marking a major technology and geographic pivot for the Japanese pharma firm.
More progress for partners’ amyloid-targeting antibody portfolio as they look to demonstrate benefit of early intervention in pre-symptomatic disease in new collaborative Phase III trial.
Join us for a quick audio roundup of five useful things to know from Scrip's recent coverage of the global biopharmaceutical industry.